Search Results - "Dejager, Sylvie"

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes by Monnier, Louis, Colette, Claude, Wojtusciszyn, Anne, Dejager, Sylvie, Renard, Eric, Molinari, Nicolas, Owens, David R

“…To define the threshold for excess glucose variability (GV), one of the main features of dysglycemia in diabetes. A total of 376 persons with diabetes…”
Get full text

Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment by Barrière, Paul, Avril, Catherine, Benmahmoud-Zoubir, Amel, Bénard, Nathalie, Dejager, Sylvie

“…The impact of patient–physician communication and levels of understanding of treatment on patient knowledge and compliance has been studied in patients…”
Get full text

Management of Type 2 Diabetes in Treatment-Naive Elderly Patients by Pratley, Richard E., Rosenstock, Julio, Pi-Sunyer, F. Xavier, Banerji, Mary Ann, Schweizer, Anja, Couturier, Andre, Dejager, Sylvie

“…Management of Type 2 Diabetes in Treatment-Naive Elderly Patients Benefits and risks of vildagliptin monotherapy Richard E. Pratley , MD 1 , Julio Rosenstock ,…”
Get full text

Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes by Monnier, Louis, Colette, Claude, Dejager, Sylvie, Owens, David

“…OBJECTIVE To assess the magnitude of the dawn phenomenon and its impact on the total glucose exposure in type 2 diabetes. RESEARCH DESIGN AND METHODS A total…”
Get full text

OPADIA Study: Is a Patient Questionnaire Useful for Enhancing Physician-Patient Shared Decision Making on Physical Activity Micro-objectives in Diabetes? by Consoli, Silla M., Duclos, Martine, Grimaldi, André, Penfornis, Alfred, Bineau, Sébastien, Sabin, Bénédicte, Pouriel, Mathilde, Freund, Eva, Dejager, Sylvie

“…Introduction Regular physical activity (PA) is recommended by all type 2 diabetes mellitus (T2DM) management guidelines. The OPADIA study aimed to determine…”
Get full text

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy by Couvert, Philippe, Giral, Philippe, Dejager, Sylvie, Gu, Jessie, Huby, Thierry, Chapman, M John, Bruckert, Eric, Carrié, Alain

“…Marked lowering of low-density-lipoprotein cholesterol (LDL-C) levels (< or =50%) with intensive statin therapy is associated with major reduction in…”
Get more information

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet by Halimi, Serge, Schweizer, Anja, Minic, Biljana, Foley, James, Dejager, Sylvie

“…Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2…”
Get full text

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies by Schweizer, Anja, Dejager, Sylvie, Foley, James E, Kothny, Wolfgang

“…Analyzing safety aspects of a drug from individual studies can lead to difficult-to-interpret results. The aim of this paper is therefore to assess the general…”
Get full text

Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes by Rosenstock, Julio, Baron, Michelle A., Dejager, Sylvie, Mills, David, Schweizer, Anja

“…Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes A 24-week, double-blind, randomized trial Julio Rosenstock , MD 1 ,…”
Get full text

Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is this of concern? by MONNIER, Louis, COLETTE, Claude, DEJAGER, Sylvie, OWENS, David

“…To assess the magnitude of the dawn phenomenon and its impact on the total glucose exposure in type 2 diabetes. A total of 248 noninsulin-treated persons with…”
Get full text

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment by Schweizer, Anja, Dejager, Sylvie

“…Introduction Patients with type 2 diabetes (T2DM) are at increased risk for renal impairment (RI) and, in addition, there is an age-related decline in renal…”
Get full text

Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial by Rosenstock, Julio, Baron, Michelle A, Dejager, Sylvie, Mills, David, Schweizer, Anja

“…OBJECTIVE:--To compare the efficacy and tolerability of vildagliptin and rosiglitazone during a 24-week treatment in drug-naïve patients with type 2 diabetes…”
Get full text

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes by Pi-Sunyer, F. Xavier, Schweizer, Anja, Mills, David, Dejager, Sylvie

“…Abstract This 24-week, double-blind, randomized, multicenter, placebo-controlled, parallel-group study performed in 354 drug-naïve patients with type 2…”
Get full text

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy by Ferrannini, E, Fonseca, V, Zinman, B, Matthews, D, Ahrén, B, Byiers, S, Shao, Q, Dejager, S

“…To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week…”
Get full text

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes by Ahrén, Bo, Schweizer, Anja, Dejager, Sylvie, Dunning, Beth E., Nilsson, Peter M., Persson, Margaretha, Foley, James E.

“…Context: Dipeptidyl peptidase-4 inhibitors act by increasing plasma levels of glucagon-like peptide-1 and suppressing excessive glucagon secretion in patients…”
Get full text

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study by Bruckert, Eric, Hayem, Gilles, Dejager, Sylvie, Yau, Caroline, Bégaud, Bernard

“…To characterize the risk factors, rate of occurrence, onset, nature and impact of mild to moderate muscular symptoms with high-dosage HMG-CoA reductase…”
Get full text

Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment by Dejager, Sylvie, Schweizer, Anja

“…Renal impairment (RI) is common among patients with type 2 diabetes mellitus (T2DM), and these patients also experience an age-related decline in renal…”
Get full text

Prediction of unplanned hospital admissions in older community dwellers using the 6-item Brief Geriatric Assessment: Results from REPERAGE, an observational prospective population-based cohort study by Beauchet, Olivier, Launay, Cyrille P., Chabot, Julia, Dejager, Sylvie, Bineau, Sebastien, Galery, Kevin, Berrut, Gilles

“…•Unplanned hospital admissions are associated with several health adverse consequences.•The 6-item brief geriatric assessment (BGA) provides a priori risk…”
Get full text

Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes by Le Pen, Claude, Bauduceau, Bernard, Ansolabehere, Xavier, Troubat, Arnaud, Bineau, Sébastien, Ripert, Mahaut, Dejager, Sylvie

“…Different countries have their own systems for evaluating new medicines, and they make decisions as to when and how each new medicine is adopted. To compare…”
Get full text

Response to comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062 by Monnier, Louis, Colette, Claude, Dejager, Sylvie, Owens, David

Get full text